Canada Radiotherapy Market Overview, 2031

Key Insights

• The Canadian radiotherapy market is characterized by a publicly funded, provincially administered healthcare system that ensures equitable access to radiation oncology services. The Canadian Institute for Health Information reports that cancer remains a leading cause of mortality nationwide, with radiotherapy serving as a cornerstone treatment for approximately 50% of all cancer patients.
• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, reflecting the widespread installed base of linear accelerators across provincial cancer agencies. Systemic radiotherapy is the fastest-growing segment, supported by Health Canada approvals for novel radiopharmaceuticals and expanded clinical indications for targeted radionuclide therapies.
• Radiotherapy systems and equipment represent the largest offering segment by revenue, consistent with the high capital intensity of advanced platforms. However, the market is structurally import-dependent, with no Canadian-headquartered manufacturer producing complete teletherapy machines. The United States accounts for an estimated 55-65% of unit imports, followed by Sweden and Germany .
• Hospitals and integrated cancer centers are the largest end-user segment, operating within provincial cancer care networks. Academic and research institutions represent the fastest-growing segment, reflecting their central role in clinical trial execution through organizations such as the NCIC Clinical Trials Group and the Canadian Association of Radiation Oncology .
• Regulatory oversight from Health Canada, which classifies radiotherapy machines as Class IV medical devices, combined with provincial radiation protection regulations and professional practice standards from the Canadian Association of Physicists, ensures high treatment quality and patient safety across the country .

Market Outlook

• According to the Bonafide research report, "Canada Radiotherapy Market Outlook, 2031," the Canada Radiotherapy market was valued at more than 140 Million in 2025. This valuation reflects the scale of Canada's publicly funded radiation oncology infrastructure, with equipment procurement and maintenance funded through provincial health budgets and capital planning processes.
• The Canadian market is expected to benefit from continued investment in cancer care infrastructure. Provinces operate centralized cancer agencies such as the Canadian Partnership Against Cancer that coordinate equipment procurement, service contracts, and technology adoption across regional health authorities. The Canadian Association of Provincial Cancer Agencies facilitates collaboration on quality radiotherapy standards .
• Technology adoption is influenced by provincial funding cycles and capital planning processes. Canadian radiation oncology programs are increasingly integrating IMRT, IGRT, and precision oncology technologies into clinical practice . However, equipment density has shown a declining trend, from 2.58 units per million persons in 2023 to projected declines through 2028, indicating that replacement cycles and capital constraints shape market dynamics .
• The market is also influenced by interprovincial variation in radiotherapy utilization. An International Cancer Benchmarking Partnership study published in The Lancet Oncology documented substantial variation across nine Canadian provinces in radiotherapy use for cancers including esophageal, rectal, and lung cancer, with 95% prediction intervals ranging from 17.8% to 82.4% for esophageal cancer .
• Long-term growth is supported by federal and provincial research funding. The Canadian Cancer Society Research Institute and the NCIC Clinical Trials Group support clinical trials that advance radiotherapy protocols and technology adoption, creating a pipeline for future clinical innovation and service expansion .

Market Dynamics

Driver: Publicly Funded Healthcare and Cancer Control Priorities
The primary driver of the Canadian radiotherapy market is the publicly funded, provincially administered healthcare system that prioritizes equitable access to cancer care. Provincial cancer agencies, coordinated through the Canadian Association of Provincial Cancer Agencies, manage radiation oncology programs and capital equipment planning . The Canadian Partnership Against Cancer, a federally funded organization, supports national cancer control strategies that include radiotherapy as a core component. This public funding model ensures consistent demand for radiotherapy equipment and services, with procurement cycles driven by population health needs, aging demographics, and clinical guidelines. The system's stability and predictability make it an attractive market for established radiotherapy equipment manufacturers and service providers.

Challenge: Capital Constraints and Equipment Aging
A significant challenge facing the Canadian radiotherapy market is the capital-intensive nature of equipment procurement within publicly funded health systems. Provincial governments face competing healthcare priorities, and radiation oncology equipment must compete with other capital investments. The density of radiation therapy equipment in Canada has shown a declining trend, from 2.58 units per million persons in 2023 to projected declines through 2028, suggesting that replacement cycles may not keep pace with population growth or aging . Additionally, the market is fully reliant on imports for complete teletherapy machines, making it vulnerable to international shipping delays, trade policy changes, and factory capacity constraints . Canadian hospitals have experienced 6-9 month delivery extensions beyond standard lead times during periods of global demand surges.



Trend: Shift Toward Evidence-Based Practice and Quality Assurance
A major trend shaping the Canadian radiotherapy market is the increasing emphasis on evidence-based practice, quality assurance, and clinical outcomes measurement. The Canadian Association of Radiation Oncology has established scope of practice guidelines for advanced techniques such as stereotactic body radiotherapy, with recommendations designed to assist departments in establishing safe and robust SBRT programs for lung, liver, and spine tumors . The Quality and Standards Committee of CARO advises the Board of Directors on standards relating to radiation therapy services, ensuring consistency across provinces . Additionally, the NCIC Clinical Trials Group's Radiation Oncology Quality Assurance Committee provides leadership and oversight for quality assurance activities in clinical trials, particularly for advanced techniques such as IMRT and IGRT .

Policies

• Health Canada regulates radiotherapy devices as medical devices under the Medical Devices Regulations (SOR/98-282). Radiotherapy machines are classified as Class IV devices the highest risk category requiring a Medical Device Establishment License for importers and distributors, as well as a product-specific Medical Device Licence before sale .
• The Health Canada review process involves assessment of quality systems (ISO 13485 compliance), clinical safety data, and radiation-emission standards. The review timeline for Class IV devices is approximately 6-8 months, with annual license renewal fees of CAD 29,405 .
• Provincial regulators impose additional requirements. Ontario's Healing Arts Radiation Protection Act and Quebec's Regulation respecting radiation-emitting devices mandate regular performance testing, staff certifications, and incident reporting. The Canadian Association of Physicists publishes consensus quality-assurance guidelines widely adopted by provinces .
• The Canadian Nuclear Safety Commission provides oversight for facilities using radioactive materials. The CNSC certifies equipment, allowing its use so long as the operator obtains a license that permits its operation .
• Key technical standards referenced include CSA C22.2 No. 60601-1 (medical electrical equipment safety), IEC 60601-2-1 (particular requirements for electron accelerators), and relevant NRC regulatory guides on radiation protection .
• The Canadian Association of Radiation Oncology's Quality and Standards Committee serves in an advisory capacity to the Board of Directors regarding standards for the provision of radiation therapy services, with representation from all regions of Canada .
• The Canadian Partnership Against Cancer and the Canadian Association of Provincial Cancer Agencies coordinate national quality initiatives, including the Canadian Partnership for Quality Radiotherapy, which supports patient-reported outcomes and patient engagement in radiotherapy programs .

Segment Analysis

Canada Radiotherapy Market By Therapy Type
• External Beam Radiotherapy (EBRT): This is the largest therapy segment in Canada, driven by the installed base of linear accelerators across provincial cancer centers and the clinical dominance of techniques including IMRT, IGRT, and VMAT. EBRT is the modality of choice for a broad spectrum of malignancies due to its effectiveness and well-established evidence base. The Canadian Association of Radiation Oncology has published scope of practice guidelines for advanced EBRT techniques such as SBRT, providing standards for safe practice across provinces .
• Internal / Brachytherapy: This segment involves the precise placement of radioactive sources inside or near the tumor. It is a mature but clinically essential segment, particularly for prostate, cervical, and breast cancers. Brachytherapy utilization is concentrated in specialized academic centers and large cancer programs due to the high level of expertise, physics support, and regulatory compliance required, including NRC and CNSC oversight for radioactive material handling.
• Systemic Radiotherapy: This is the fastest-growing therapy segment, fueled by Health Canada approvals for novel radiopharmaceuticals and targeted radionuclide therapies. These therapies are gaining traction for treating specific malignancies including metastatic prostate cancer and neuroendocrine tumors. Growth is supported by clinical trial activity through the NCIC Clinical Trials Group and collaboration with international research networks .

Canada Radiotherapy Market By Offering
• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by the high capital cost of advanced treatment delivery systems including linear accelerators, with import customs value typically ranging from CAD 1.8 million to CAD 3.5 million per unit . The market is structurally import-dependent, with no Canadian-headquartered manufacturer producing complete teletherapy machines. The United States is the largest source country, accounting for an estimated 55-65% of unit imports, with Sweden and Germany contributing roughly 15-20% each .
• Software & Services: This is the fastest-growing segment, reflecting increasing digitalization of radiation oncology. The software component includes advanced treatment planning systems, AI-powered contouring and dose optimization tools, and patient data management platforms. The services component encompasses installation, comprehensive maintenance, clinical training, physics support, and technical support. Independent service organizations hold an estimated 5-10% of the service contract market, mainly for older-generation machines no longer supported by manufacturers .

Canada Radiotherapy Market By Application
• Breast Cancer: This is the largest application segment due to high incidence and the well-established role of radiotherapy in breast-conserving therapy and post-mastectomy settings. Canadian clinical practice follows evidence-based guidelines, with techniques including hypofractionated whole-breast irradiation and accelerated partial breast irradiation contributing to steady demand.
• Prostate Cancer: A major application area, with widespread use of both EBRT techniques including SBRT and brachytherapy. Canadian radiation oncology programs have adopted advanced image guidance for prostate cancer treatment, consistent with international standards.
• Lung Cancer: This segment is clinically significant, with a growing role for SBRT in early-stage and oligometastatic disease. The CARO-SBRT Task Force has published guidelines specific to lung, liver, and spine SBRT to ensure safe practice across Canadian departments .
• Head & Neck Cancer: A critical application due to anatomical complexity, requiring highly conformal radiation delivery to spare adjacent critical structures. IMRT and VMAT are standard, and this segment often leads adoption of advanced image-guided platforms.
• Central Nervous System / Brain: This is the fastest-growing application, driven by stereotactic radiosurgery for brain metastases and advanced MR-guided radiotherapy for high-grade gliomas. Canadian academic centers are active in clinical research through the NCIC Clinical Trials Group .
• Gastro-intestinal: Applications include esophageal, rectal, liver, and pancreatic cancers. An International Cancer Benchmarking Partnership study documented substantial interprovincial variation in radiotherapy use for gastrointestinal cancers, with wide 95% prediction intervals observed for esophageal cancer (17.8-82.4%) and rectal cancer (35.5-55.2%) .
• Other Applications: Includes gynecological, hematological, pediatric, and palliative care indications, contributing to overall market diversity.

Canada Radiotherapy Market By End User
• Hospitals & Integrated Cancer Centers: This is the largest end-user segment, as these institutions operate within provincial cancer care networks and provide comprehensive, multidisciplinary cancer care. They possess the infrastructure and capital resources to invest in advanced radiotherapy technologies and typically operate multiple linear accelerators and brachytherapy programs.
• Standalone Radiotherapy Centers: This segment is growing as care shifts toward community-based settings. These centers offer specialized radiotherapy services and focus on operational efficiency and patient access, representing growth areas for both capital equipment and service contracts.
• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in advancing the field through clinical trials and technology validation. The NCIC Clinical Trials Group and its Radiation Oncology Quality Assurance Committee provide leadership for clinical trials involving radiation therapy, ensuring high-quality data for treatment decisions .
• Other Healthcare Facilities: Includes community hospitals, rural health clinics, and palliative care facilities, providing regional access to radiation oncology services.

Canada Radiotherapy Market Economics

• Service contract pricing and maintenance costs vary by equipment type, with advanced systems commanding higher annual costs. Competition is primarily based on installed-base loyalty, service responsiveness, and clinical workflow integration rather than price .
• Equipment procurement in Canada is conducted through provincial health authorities and cancer agencies, with group purchasing and competitive tendering processes shaping vendor selection and service agreements. Multi-year agreements are common to ensure predictable maintenance costs and equipment uptime.
• The Canadian market is fully reliant on imports for complete teletherapy machines, with domestic firms participating only as component suppliers for example, custom radiation shielding enclosures, patient positioning systems, and software modules .
• Tariff treatment is generally favorable for radiotherapy equipment. Linear accelerators are classified under HS 9022.21 and are generally duty-free under the USMCA for U.S.-origin goods, and subject to most-favored-nation rates of 0-2% for European-origin units .
• The trade balance in this product category is heavily negative, with imports exceeding exports by a factor of 30:1 or more in value terms. Used systems are occasionally decommissioned and sold to Latin American or Middle Eastern markets, but volume is fewer than five units per year .
• For provincial health systems, equipment availability directly affects patient access, surgical schedules, and cancer care wait times. Unplanned downtime can disrupt treatment schedules and impact patient outcomes, reinforcing the economic case for comprehensive service contracts.
• The cost of cybersecurity maintenance is emerging as a new economic factor, requiring dedicated budget allocation for software patch management and vulnerability remediation across connected radiotherapy device fleets.

Market Outlook by Infrastructure, Investment and Industry Development

• Provincial cancer agencies are centralizing radiation oncology operations and investing in enterprise asset management platforms to improve operational efficiency, standardize treatment protocols, and optimize maintenance spending across regional health authorities.
• Investment in community-based radiotherapy centers continues to expand the equipment base beyond tertiary hospitals, creating new demand for distributed maintenance and service logistics across broader geographic regions.
• Digital transformation is enabling remote diagnostics, predictive maintenance, and real-time performance monitoring of radiotherapy equipment, shifting service delivery toward proactive and condition-based maintenance models.
• Cybersecurity requirements are becoming a core component of radiotherapy equipment maintenance, driving investment in software patch management and vulnerability remediation for connected devices to comply with Health Canada guidance.
• Workforce development programs in medical physics, radiation therapy, and biomedical engineering are expanding through Canadian universities and professional organizations to address documented specialist shortages, particularly in rural and remote regions.
• The Canadian Association of Radiation Oncology and the Canadian Association of Physicists continue to develop professional practice standards and quality assurance guidelines that shape technology adoption and service delivery models.
• The long-term outlook remains positive as cancer incidence continues to rise, the population ages, and the critical role of radiotherapy in comprehensive cancer care becomes increasingly recognized across Canada's publicly funded healthcare system.



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Radiotherapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• External Beam Radiotherapy (EBRT)
• Internal / Brachytherapy
• Systemic Radiotherapy

By Offering
• Radiotherapy Systems/Equipment
• Software & Services

By Application
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Head & Neck Cancer
• Central Nervous System / Brain
• Gastro-intestinal
• Other Applications

By End User

• Hospitals & Integrated Cancer Centers
• Standalone Radiotherapy Centers
• Academic/Research Institutions
• Other Healthcare Facilities